Oral Presentation (MP-8)

Lack of Antibody Formation Against Inactivated Avian Influenza Virus in Ducks and Chickens After Intranasally Immunization

Okki Nadia Poetri1*, Retno Damayanti Soejoedono1, Ni Luh Putu Ika Mayasari1, Ekowati Handharyani2, Novera Nirmalasanti3

1Department of Animal Diseases and Public Health, Faculty of Veterinary Medicine, Bogor Agricultural University, Jl. Agatis Kampus IPB Dramaga, Bogor 16680, West Java, Indonesia
2Department of Clinic, Reproduction and Pathology, Faculty of Veterinary Medicine, Bogor Agricultural University, Jl. Agatis Kampus IPB Dramaga, Bogor 16680, West Java, Indonesia
3Tanjung Priok Agriculture Quarantine Station, Indonesian Agriculture Quarantine Agency, Jl. Enggano No.17, Tanjung Priok 14310, North Jakarta, Indonesia

*Corresponding author’s email: diapoetri@gmail.com

Keywords: antibody, avian influenza virus, duck, ELISA.

INTRODUCTION
Vaccination is one of control strategies implemented in endemic countries such as Egypt and Indonesia [1,2]. Most commercial AI vaccines available in Indonesia are adjuvanted inactivated AI vaccines applied through intramuscular routes. Vaccine application by subcutaneous or intramuscular injection can cause pain and stress in poultry, the route of vaccine through the nasal drip (intranasal) is a more convenient and painless. However, respiratory applied inactivated influenza is poorly immunogenic. Therefore prior to developing inactivated intranasal vaccine, it is necessary to study antibody response to inactivated AI virus which exposed through intranasal route. The aim of our research was to determined antibody response of ducks and chickens against avian influenza virus (AIV) subtype H5N1 after intranasally immunization.

MATERIALS AND METHODS
A total of 22 AIV antibody negative ducks and 50 specified pathogen free (SPF) chickens were used in this research. Each animal groups were divided into two groups: control group and immunization group. Birds in control group were inoculated using 0.1 ml presterilized phosphate buffer saline (PBS), whilst the other groups were inoculated using 0.1 ml inactivated AIV subtype H5N1 clade 2.3.2 (A/Ck/SR1/15) containing 128 hemaglutinin unit (HAU)/25µl intranasally. Serum samples were collected at day 1, 4, 7 and 10 post inoculation. Antibody against AIV were determined using Enzyme Linked Immunosorbent Assay (ELISA) technique.

RESULT AND DISCUSSION
Our results showed that 3 of 13 (23%) ducks inoculated with inactivated AI virus had specific antibodies against AI, while others did not form specific antibodies against AI. Two of the three ducks with specific antibodies were positive only on day 1 after inoculation, and only one duck had positive AI antibodies on day 1.4,7, and 10 after inoculation. Whilst, in chickens, only 2 of 25 (8%) chickens inoculated with inactivated AI virus had antibodies specific to AI, antibodies detected on day 4 after inoculation. All birds among control group were not develop a specific antibody against AIV.

Our result were in accordance to earlier study by De Geus et al. [3] showed that adjuvanted inactivated AI H9N2 with chitosan or aluminum OH applied through intranasal route were not able to induce specific antibody formation. However other study by Worall et al. [4] were in contrary with our result, their study showed that inactivated AI H5N1 vaccine with chitosan and sialidase applied through intanasal route were able to stimulated the formation of IgA specific to AI. In this study, we only evaluated the presence of antibodies in serum IgG, and did not evaluate the presence of specific IgA from the mucosa. Provision of antigens via intranasal route should stimulate local immune formation better.

CONCLUSION
Lack of antibody formation might be due to low concentration of virus or most likely due to absence of adjuvanta, showing the need of improving immunogenecity of inactived AIV if we want to develop intranasally vaccine.

ACKNOWLEDGMENTS
This research was funded by Ministry of Research, Technology and Higher Education of Republic Indonesia in 2017.

REFERENCES

